Case study: Finding impurities and controlling formations at release
Posted: 21 April 2021 | ADARE Pharma Solutions | No comments yet
Adare Pharma Solutions was selected to identify and remediate impurities found during analysis of an Active Pharmaceutical Ingredient (API). Adare’s scientists used cause-and-effect diagramming to determine the cause of two impurities occurring during analysis for the unstable API. The product is now manufactured by Adare and provided in a sealed bottle with desiccant.
Related content from this organisation
- EPR Podcast Episode 26 – Navigating Nitrosamine Impurities – Jason Brown, Adare Pharma Solutions
- Maintaining EU MDR certification: a spotlight on post‑market clinical follow-up
- Formulation, Development & Delivery In-Depth Focus 2021
- Scientific briefing: Formulation-Monodisperse CR quetiapine microspheres
- Scientific briefing: Formulation of aqueous core poly (lactic acid) microcapsules